Iverson Genetic Diagnostics Release: Centers for Medicare & Medicaid Services Approves Clinical Study of Genetic Test to Predict Patient Response to Leading Anticoagulant Drug Warfarin
7/27/2010 7:36:47 AM
ATLANTA--(BUSINESS WIRE)--Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.